10-QPeriod: Q1 FY2009

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2009

Filed May 6, 2009For Securities:DXCM

Summary

DexCom, Inc. reported its first quarter 2009 financial results, showing continued revenue growth driven by its continuous glucose monitoring (CGM) systems, specifically the SEVEN and the newly launched SEVEN PLUS. While product revenue increased to $2.7 million from $1.8 million in the prior year's quarter, the company still operates at a loss, with a net loss of $13.1 million for Q1 2009. This loss, however, narrowed slightly from $13.8 million in Q1 2008, partly due to significant development grant revenue of $2.5 million and a reduction in R&D expenses. The company ended the quarter with a stronger cash position, bolstered by a successful follow-on public offering that brought in $45.6 million in net proceeds. This capital infusion is crucial as DexCom continues to invest heavily in research and development for next-generation products and seeks broader market and payer adoption, which remains a key challenge. Despite the ongoing losses, the company's strategic focus on expanding its product line and international presence, coupled with strong revenue growth, indicates a positive trajectory for long-term market penetration in the diabetes management sector.

Key Highlights

  • 1Product revenue increased by 46.5% to $2.7 million in Q1 2009 compared to $1.8 million in Q1 2008.
  • 2Development grant revenue significantly increased to $2.5 million in Q1 2009, up from $38,000 in Q1 2008, largely due to new collaboration agreements.
  • 3Net loss slightly decreased to $13.1 million ($0.33 per share) in Q1 2009 from $13.8 million ($0.47 per share) in Q1 2008.
  • 4Operating expenses saw a decrease in R&D ($1.6M reduction) but an increase in SG&A ($1.5M increase), leading to a slight overall decrease in total operating expenses.
  • 5The company raised $45.6 million in net proceeds from a follow-on public offering in Q1 2009, significantly improving its liquidity.
  • 6Cash and cash equivalents, including short-term marketable securities, stood at $61.5 million at the end of the quarter.
  • 7DexCom received FDA approval for its third-generation SEVEN PLUS CGM system in February 2009 and began commercialization.

Frequently Asked Questions

In the first quarter of 2009, DexCom reported a net loss of $13.1 million, or $0.33 per share, a slight improvement from a net loss of $13.8 million, or $0.47 per share, in the same quarter of 2008. Product revenue grew by 46.5% to $2.7 million, driven by increased sales volume and higher average selling prices. Significant development grant revenue of $2.5 million also contributed to the top line.

DexCom's liquidity improved significantly due to a follow-on public offering that generated $45.6 million in net proceeds in Q1 2009. The company ended the quarter with $61.5 million in cash, cash equivalents, and short-term marketable securities. Management believes this, along with projected contributions from partnerships, will be sufficient to meet its cash requirements for at least the next twelve months, supporting ongoing commercialization and R&D activities.

DexCom received FDA approval for its third-generation SEVEN PLUS continuous glucose monitoring (CGM) system in February 2009 and began commercializing it. The company is also continuing development of a fourth-generation ambulatory product, a pediatric and pregnancy indication, and an in-hospital CGM system in collaboration with Edwards Lifesciences. Efforts to secure wider reimbursement from third-party payors remain a critical focus.

Key risks include the potential for market acceptance issues by physicians and patients, challenges in manufacturing and scaling production, limited reimbursement from third-party payors, intense competition from established medical device companies, and ongoing patent litigation with Abbott Diabetes Care. The company also faces risks related to its debt obligations and potential dilution from the conversion of convertible senior notes.